Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tekmira Pharmaceuticals has announced a research collaboration with Bristol-Myers Squibb using Tekmira's stable nucleic-acid lipid particle technology to deliver small interfering RNAs to specific organs and tissues outside of the liver.
Subscribe to our email newsletter
The relationship between Tekmira and Bristol-Myers Squibb builds upon earlier work conducted at Bristol-Myers Squibb using small interfering RNA (siRNA) delivery technology provided by privately held Protiva Biotherapeutics. In May, Protiva and Tekmira combined their businesses to create a leader in the field of RNA interference (RNAi) therapeutics, according to Tekmira.
Mark Murray, Tekmira’s president and CEO, said: “Our relationship with Bristol-Myers Squibb is consistent with our strategy to work with global pharmaceutical leaders to expand the therapeutic potential of our leading RNAi delivery technology. At the same time, this work complements our internal product development initiatives as we advance our own RNAi therapeutics to treat serious human diseases.”
The initial collaboration between Bristol-Myers Squibb and Protiva focused on validating certain gene targets using siRNAs provided by Bristol-Myers Squibb and employed a number of different stable nucleic-acid lipid particle (SNALP) formulations. SNALP is Tekmira’s proprietary lipid nanoparticle technology for the delivery of RNAi drugs, including siRNAs.